A Mixture of Essential Oils from Three Cretan Aromatic Plants Inhibits SARS-CoV-2 Proliferation: A Proof-of-Concept Intervention Study in Ambulatory Patients.
COVID-19
SARS-CoV-2
effectiveness
essential oils
natural products
Journal
Diseases (Basel, Switzerland)
ISSN: 2079-9721
Titre abrégé: Diseases
Pays: Switzerland
ID NLM: 101636232
Informations de publication
Date de publication:
09 Aug 2023
09 Aug 2023
Historique:
received:
15
07
2023
revised:
04
08
2023
accepted:
07
08
2023
medline:
22
8
2023
pubmed:
22
8
2023
entrez:
22
8
2023
Statut:
epublish
Résumé
The need for effective therapeutic regimens for non-critically ill patients during the COVID-19 pandemic remained largely unmet. Previous work has shown that a combination of three aromatic plants' essential oils (CAPeo) ( A total of 69 adult patients were included in a clinical proof-of-concept (PoC) intervention study. Family physicians implemented the observational study in two arms (intervention group and control group) during three study periods (IG The PoC study found that the number and frequency of general symptoms, including general fatigue, weakness, fever, and myalgia, decreased following CAPeo administration. By Day 7, the average presence (number) of symptoms decreased in comparison with Day 1 in IG (4.7 to 1.4) as well as in CG (4.0 to 3.1), representing a significant decrease in the cumulative presence in IC (-3.3 vs. -0.9, Our findings suggest that CAPeo possesses potent antiviral activity against SARS-CoV-2 in addition tο its effect against influenza A and B and human rhinovirus HRV14 strains. The early and effective impact on alleviating key symptoms of COVID-19 may suggest this mixture can act as a complementary natural agent for patients with mild COVID-19.
Identifiants
pubmed: 37606476
pii: diseases11030105
doi: 10.3390/diseases11030105
pmc: PMC10443288
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Science. 2020 Aug 21;369(6506):1010-1014
pubmed: 32540901
Molecules. 2022 Jun 24;27(13):
pubmed: 35807306
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
J Ethnopharmacol. 2021 Apr 24;270:113869
pubmed: 33485973
Int J Mol Sci. 2023 May 31;24(11):
pubmed: 37298539
Pharmacol Res Perspect. 2021 Aug;9(4):e00798
pubmed: 34128351
Sci Rep. 2021 May 12;11(1):10124
pubmed: 33980931
Front Pharmacol. 2022 Aug 19;13:926507
pubmed: 36059994
Am J Clin Nutr. 2005 Jan;81(1 Suppl):230S-242S
pubmed: 15640486
Nat Commun. 2023 Jul 15;14(1):4231
pubmed: 37454219
J Funct Foods. 2023 Jun;105:105544
pubmed: 37155488
Eur J Med Chem. 2023 Sep 5;257:115503
pubmed: 37229831
Science. 2020 Nov 27;370(6520):1110-1115
pubmed: 33037066
Front Cell Infect Microbiol. 2020 Nov 25;10:587269
pubmed: 33324574
N Engl J Med. 2021 Jan 21;384(3):238-251
pubmed: 33332778
Sci Total Environ. 2019 Dec 1;694:133681
pubmed: 31756796
Front Pharmacol. 2020 Nov 24;11:522213
pubmed: 33390932
BMJ. 2023 May 23;381:1111
pubmed: 37220942
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
J Ethnopharmacol. 2015 Apr 2;163:157-66
pubmed: 25645191
Metabol Open. 2021 Dec;12:100141
pubmed: 34693242
Trends Genet. 2020 Nov;36(11):892-893
pubmed: 32943208
BMC Complement Altern Med. 2017 Sep 21;17(1):466
pubmed: 28934952
Int Immunopharmacol. 2021 Jan;90:107228
pubmed: 33302035
Int Immunopharmacol. 2021 Feb;91:107262
pubmed: 33338863
Fam Pract. 2021 Nov 24;38(6):811-825
pubmed: 33586769
Ann Intern Med. 2020 May 05;172(9):577-582
pubmed: 32150748
J Intern Med. 2020 Sep;288(3):335-344
pubmed: 32352202
Front Pharmacol. 2020 Aug 07;11:1189
pubmed: 32848790
Biomed Pharmacother. 2002 Aug;56(6):276-82
pubmed: 12224598
Nat Hum Behav. 2020 Sep;4(9):972-982
pubmed: 32848231
BMC Infect Dis. 2020 Nov 6;20(1):811
pubmed: 33158425
Euro Surveill. 2020 Aug;25(32):
pubmed: 32794447
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238